Insider Selling: Medpace (NASDAQ:MEDP) CEO Sells 154 Shares of Stock

Posted by Brian Himes on Sep 29th, 2026

Medpace Holdings, Inc. (NASDAQ:MEDP – Get Free Report) CEO August Troendle sold 154 shares of Medpace stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $620.60, for a total value of $95,572.40. Following the completion of the sale, the chief executive officer owned 389,302 shares of the company’s stock, valued at approximately $241,600,821.20. The trade was a 0.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Medpace Stock Performance

Medpace stock traded up $6.17 during trading hours on Tuesday, reaching $622.11. 249,674 shares of the company’s stock traded hands, compared to its average volume of 331,499. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90. The firm has a market capitalization of $17.36 billion, a price-to-earnings ratio of 36.47, a PEG ratio of 2.76 and a beta of 1.15. The firm’s 50 day moving average is $596.41 and its 200-day moving average is $517.30.

Medpace (NASDAQ:MEDP – Get Free Report) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.98 by $0.27. The company had revenue of $707.33 million for the quarter, compared to analyst estimates of $689.51 million. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter last year, the firm earned $3.10 EPS. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. Analysts predict that Medpace Holdings, Inc. will post 17.54 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of MEDP. State Street Corp increased its stake in Medpace by 4.2% in the second quarter. State Street Corp now owns 710,895 shares of the company’s stock valued at $376,483,000 after purchasing an additional 28,666 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Medpace by 38.9% during the second quarter. The Manufacturers Life Insurance Company now owns 20,043 shares of the company’s stock worth $10,615,000 after purchasing an additional 5,610 shares in the last quarter. Sequoia Financial Advisors LLC boosted its position in shares of Medpace by 8.2% during the second quarter. Sequoia Financial Advisors LLC now owns 1,108 shares of the company’s stock worth $587,000 after purchasing an additional 84 shares in the last quarter. Tidal Investments LLC grew its holdings in shares of Medpace by 8.0% in the 2nd quarter. Tidal Investments LLC now owns 6,155 shares of the company’s stock valued at $3,260,000 after buying an additional 458 shares during the period. Finally, Archford Capital Strategies LLC grew its holdings in shares of Medpace by 5.4% in the 2nd quarter. Archford Capital Strategies LLC now owns 1,658 shares of the company’s stock valued at $878,000 after buying an additional 85 shares during the period. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have commented on MEDP. Royal Bank Of Canada lifted their target price on shares of Medpace from $484.00 to $692.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. BMO Capital Markets raised their price target on Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research report on Friday, July 24th. Jefferies Financial Group reaffirmed a “hold” rating on shares of Medpace in a research note on Monday, September 14th. Truist Financial upped their price objective on Medpace from $462.00 to $609.00 and gave the company a “hold” rating in a report on Friday, July 24th. Finally, Robert W. Baird increased their target price on Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Three analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $595.20.

Get Our Latest Stock Report on Medpace

About Medpace

(Get Free Report)

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the product development process, from early planning and protocol design through clinical trials, regulatory submission and post-marketing activities.

Its services include clinical trial management, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance and regulatory consulting.